Review: senolytic and senomorphic strategies for ovarian aging remain preclinical
This review links cellular senescence to ovarian aging and evaluates senolytic and senomorphic approaches, but states these interventions remain largely mechanistic and preclinical, with uncertain translational potential in humans. [1]
Automatic summary · not editorially reviewed
The key findings
Ovarian aging is described as progressive depletion of the primordial follicle reserve and declining oocyte quality, culminating in menopause and associated systemic comorbidities. [1]
The review evaluates preclinical efficacy of senolytics and senomorphics for preserving ovarian reserve, mitigating SASP-driven inflammation and fibrosis, and extending reproductive lifespan. [1]
Current senolytic and senomorphic interventions for ovarian aging remain largely mechanistic and preclinical, and their translational potential in humans is still uncertain. [1]
The source at a glance
- Study type / format
- Narrative review (abstract only)
- Population / context
- Women and ovarian biology in the context of ovarian aging, as described in the review
- Summary based on
- Study abstract
- Original publication
- June 17, 2026
Senescence as driver of ovarian aging
The review describes ovarian aging as progressive depletion of the primordial follicle reserve and declining oocyte quality, ending in menopause and associated systemic comorbidities. Cellular senescence is presented as a central driver, acting through cell-cycle arrest pathways and a proinflammatory senescence-associated secretory phenotype that disrupts the follicular niche and stromal architecture. The authors synthesize molecular hallmarks, including genomic instability, mitochondrial dysfunction, dysregulated nutrient sensing via PI3K/AKT/mTOR, proteostatic failure, epigenetic drift and inflammasome activation, into a unified framework for therapeutic intervention.
Supporting source [1]
Preclinical senolytics and senomorphics evaluated
The review critically evaluates preclinical efficacy of senolytics such as dasatinib plus quercetin, navitoclax and fisetin, and of senomorphics such as rapamycin, metformin, melatonin and NLRP3 inhibitors. According to the source, these were assessed for preserving ovarian reserve, mitigating inflammation and fibrosis driven by the senescence-associated secretory phenotype, and extending reproductive lifespan. The authors emphasize multimodal biomarkers, including AMH, AFC, SASP analytes, follicular fluid signatures and exosomal RNAs, as essential for clinical translation, alongside ovary-directed delivery systems to improve specificity and safety.
Supporting source [1]
Translational status uncertain in this review
The source states that current senolytic and senomorphic interventions for ovarian aging remain largely at the mechanistic and preclinical stages, and that their translational potential in humans is still uncertain. The review positions itself as bridging ovarian geroscience with emerging senotherapeutics and charting a roadmap from bench to bedside, offering potential to combat ovarian aging and safeguard women's reproductive and systemic health. These are proposed directions, not demonstrated human benefits.
Supporting source [1]
How to interpret this
This is an abstract of a review; the full text was not reviewed. The abstract reports no human trial data, sample sizes or follow-up, and the interventions described are preclinical or proposed.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Alsirhani AM, El-Nablaway M, Yousef TA, Ali Elewa YH, Al-Hazani TMI. · europepmc.org · June 17, 2026